Drug Profile
3874 H3
Alternative Names: Heptaene antifungalLatest Information Update: 14 May 2003
Price :
$50
*
At a glance
- Originator Aventis
- Class Antifungals
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 14 May 2003 Discontinued - Preclinical for Mycoses in France (unspecified route)
- 14 May 2003 Discontinued - Preclinical for Mycoses in Germany (unspecified route)
- 13 Nov 2001 No-Development-Reported for Mycoses in France (Unknown route)